Journal article
Something's got to give: psychiatric disease on the rise and novel drug development on the decline
Drug discovery today, v 18(3-4), pp 202-206
Feb 2013
PMID: 22980124
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Research and development of drugs for psychiatric disease is currently in a state of decline. Despite the increasing prevalence and healthcare costs of psychiatric disease, the costly and unpredictable drug development process has led to decreased public and investor confidence in the abilities of companies to develop safe and efficacious drugs. Industrial research in this disease area is therefore being scaled back owing to various scientific, corporate, financial and legal factors. This review will consider how these factors contribute to the current status of psychiatric drug development and offer several avenues forward to spur reinvestment in this type of research. Such a shift is needed to reduce the burden psychiatric disease imposes on the healthcare system and its patient populations.
Metrics
Details
- Title
- Something's got to give: psychiatric disease on the rise and novel drug development on the decline
- Creators
- Daniel J Chandler - Drexel University
- Publication Details
- Drug discovery today, v 18(3-4), pp 202-206
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurobiology and Anatomy
- Web of Science ID
- WOS:000315017000012
- Scopus ID
- 2-s2.0-84873095820
- Other Identifier
- 991019168757404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Pharmacology & Pharmacy